

Financial news for REPH dated on 2020-05-15: The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO

Financial news for REPH dated on 2020-05-14: Stocks That Hit 52-Week Lows On Thursday

Financial news for REPH dated on 2020-05-14: The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger

Financial news for REPH dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for REPH dated on 2020-05-13: Stocks That Hit 52-Week Lows On Wednesday

Financial news for REPH dated on 2020-05-12: Oppenheimer Maintains Outperform on Recro Pharma, Lowers Price Target to \$12

Financial news for REPH dated on 2020-05-12: The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands \$384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings

Financial news for REPH dated on 2020-05-12: 78 Biggest Movers From Yesterday

Financial news for REPH dated on 2020-05-11: Mid-Afternoon Market Update: NASDAQ Rises Over 100 Points; Amneal Pharmaceuticals Shares Surge On Upbeat Results

Financial news for REPH dated on 2020-05-11: 54 Stocks Moving In Monday's Mid-Day Session

Financial news for REPH dated on 2020-05-11: Mid-Day Market Update: Recro Pharma Falls After Q1 Results; MyoKardia Shares Climb

Financial news for REPH dated on 2020-05-11: Stocks That Hit 52-Week Lows On Monday

Financial news for REPH dated on 2020-05-11: Mid-Morning Market Update: Markets Mostly Lower; Cardinal Health Beats Q3 Estimates

Financial news for REPH dated on 2020-05-11: Recro Pharma shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.

Financial news for REPH dated on 2020-05-11: 15 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for REPH dated on 2020-05-11: Recap: Recro Pharma Q1 Earnings

Financial news for REPH dated on 2020-05-11: Recro Pharma Q1 EPS \$(0.330) Misses \$(0.030) Estimate, Sales \$21.777M Beat \$19.450M Estimate

Financial news for REPH dated on 2020-05-10: The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

Financial news for REPH dated on 2020-03-31: 80 Biggest Movers From Yesterday

Financial news for REPH dated on 2020-03-30: 55 Stocks Moving In Monday's Mid-Day Session

Financial news for REPH dated on 2020-03-30: Mid-Day Market Update: Dow Jumps Over 400 Points; Plus Therapeutics Shares Spike Higher

Financial news for REPH dated on 2020-03-05: Stephens & Co. Maintains Overweight on Recro Pharma, Lowers Price Target to \$18

Financial news for REPH dated on 2020-03-05: 92 Biggest Movers From Yesterday

Financial news for REPH dated on 2020-03-04: Mid-Afternoon Market Update: Dow Jumps Over 800 Points; Cardlytics Shares Slide

Financial news for REPH dated on 2020-03-04: Afternoon Market Stats In 5 Minutes

Financial news for REPH dated on 2020-03-04: 60 Stocks Moving In Wednesday's Mid-Day Session

Financial news for REPH dated on 2020-03-04: Mid-Day Market Update: Owens & Minor Falls On Weak Sales; Collect Biotechnology Shares Climb

Financial news for REPH dated on 2020-03-04: Mid-Morning Market Update: Markets Open Higher; Dollar Tree Posts Mixed Q4 Results

Financial news for REPH dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for REPH dated on 2020-02-14: The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering

Financial news for REPH dated on 2019-12-27: Stocks That Hit 52-Week Highs On Friday

Financial news for REPH dated on 2019-12-27: The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

Financial news for REPH dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for REPH dated on 2019-12-19: Stocks That Hit 52-Week Highs On Thursday

Financial news for REPH dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for REPH dated on 2019-12-03: Stocks That Hit 52-Week Highs On Tuesday

Financial news for REPH dated on 2019-12-03: The Daily Biotech Pulse: Astellas To Buy Audentes For \$3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial

Financial news for REPH dated on 2019-11-29: Stocks That Hit 52-Week Highs On Friday

Financial news for REPH dated on 2019-11-26: Stephens & Co. Maintains Overweight on Recro Pharma, Lowers Price Target to \$19

Financial news for REPH dated on 2019-11-22: The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

Financial news for REPH dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for REPH dated on 2019-11-13: Stocks That Hit 52-Week Highs On Wednesday

Financial news for REPH dated on 2019-11-08: Stocks That Hit 52-Week Highs On Friday

Financial news for REPH dated on 2019-11-06: The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings

Financial news for REPH dated on 2019-11-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for REPH dated on 2019-11-05: Recro Pharma Board Approves Separation Of Acute Care Business Unit; Declares Special Dividend For Baudax Bio Common Stock: For Every 2.5 Shares Of Recro, Shareholders Will Receive 1 Share Of Baudax

Financial news for REPH dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for REPH dated on 2019-11-04: Stocks That Hit 52-Week Highs On Monday

Financial news for REPH dated on 2019-11-01: Stocks That Hit 52-Week Highs On Friday

Financial news for REPH dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for REPH dated on 2019-10-31: FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application

Financial news for REPH dated on 2019-10-30: Stocks That Hit 52-Week Highs On Wednesday

Financial news for REPH dated on 2019-10-25: Stocks That Hit 52-Week Highs On Friday

Financial news for REPH dated on 2019-10-21: Stocks That Hit 52-Week Highs On Monday

Financial news for REPH dated on 2019-10-17: Benzinga's Top Upgrades, Downgrades For

October 17, 2019

Financial news for REPH dated on 2019-10-17: Stephens & Co. Initiates Coverage On Recro Pharma with Overweight Rating, Announces \$14 Price Target

Financial news for REPH dated on 2019-08-22: Stocks That Hit 52-Week Highs On Thursday

Financial news for REPH dated on 2019-08-22: The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study

Financial news for REPH dated on 2019-08-14: Stocks That Hit 52-Week Highs On Wednesday

Financial news for REPH dated on 2019-08-09: The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2

Financial news for REPH dated on 2019-08-08: Stocks That Set New 52-Week Highs Thursday

Financial news for REPH dated on 2019-08-08: Recro Pharma Reports Plan To Spin Out Acute Care Segment, Have CDMO Business, Acute Care Business Operate As 2 Separately Traded Public Cos.

Financial news for REPH dated on 2019-08-08: Recro Pharma Raises FY19 Sales Guidance From \$85M-\$87M To \$91M-\$94M vs \$91.3M Estimate

Financial news for REPH dated on 2019-08-08: Recro Pharma Q2 EPS \$(0.13) Beats \$(0.42) Estimate, Sales \$31.3M Beat \$23.59M Estimate

Financial news for REPH dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for REPH dated on 2019-05-10: Recro Pharma Q1 EPS \$(0.10) vs \$(0.65) In Same Qtr. Last Year, Sales \$25.065M Beat \$20.51M Estimate

Financial news for REPH dated on 2019-04-16: Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville

Financial news for REPH dated on 2019-04-11: Recro Pharma Highlights Presentation Of New Meta-Analysis For IV Meloxicam At The 44th Annual Regional Anesthesiology And Acute Pain Medicine Meeting

Financial news for REPH dated on 2019-04-05: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Apr. 5, 2019

Financial news for REPH dated on 2019-04-05: 52 Biggest Movers From Yesterday

Financial news for REPH dated on 2019-04-04: Mid-Afternoon Market Update: Dow Up 135 Points; Recro Pharma Shares Spike Higher

Financial news for REPH dated on 2019-04-04: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for REPH dated on 2019-04-04: Mid-Day Market Update: Resources Connection Falls After Q3 Results; Tonix Pharmaceuticals Shares Surge

Financial news for REPH dated on 2019-04-04: Mid-Morning Market Update: Markets Open Higher; Constellation Brands Tops Q4 Estimates

Financial news for REPH dated on 2019-04-04: Recro Pharma shares are trading higher after the company raised FY19 sales guidance from \$80 million to \$85-\$87 million, compared to the \$85.12 million estimate; the company also announced a reorganization plan in its acute care segment.

Financial news for REPH dated on 2019-04-04: 32 Stocks Moving In Thursday's Pre-Market Session

Financial news for REPH dated on 2019-04-04: The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Drovers, Silk Road, NGM Biopharma To Debut

Financial news for REPH dated on 2019-04-03: Recro Pharma shares are trading higher after the company announced a reorganization plan in its acute care segment and raised FY19 sales guidance.

Financial news for REPH dated on 2019-04-03: Recro Pharma Raises FY19 Sales Guidance From \$80M To \$85M-\$87M vs \$85.12M

Financial news for REPH dated on 2019-04-03: Recro Pharma Restructures Acute Care Segment, Plans To Reduce Staff

Financial news for REPH dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for REPH dated on 2019-03-26: 52 Biggest Movers From Yesterday

Financial news for REPH dated on 2019-03-25: Mid-Afternoon Market Update: DarioHealth Falls Following Q4 Results; Avaya Shares Jump

Financial news for REPH dated on 2019-03-25: 41 Stocks Moving In Monday's Mid-Day Session

Financial news for REPH dated on 2019-03-25: Mid-Day Market Update: Iterum Therapeutics Gains After Q4 Results; Proteostasis Therapeutics Shares Slide

Financial news for REPH dated on 2019-03-25: More Pain For Recro Pharma: FDA Rejects Meloxicam NDA For Second Time

Financial news for REPH dated on 2019-03-25: Mid-Morning Market Update: Markets Open Lower; Winnebago Industries Posts Mixed Q4 Results

Financial news for REPH dated on 2019-03-25: Recro Pharma shares are trading lower after the company's marketing application for IV Meloxicam was rejected by the FDA.

Financial news for REPH dated on 2019-03-25: Roth Capital Downgrades Recro Pharma to Neutral, Announces \$7.50

Financial news for REPH dated on 2019-03-25: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for REPH dated on 2019-03-23: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for REPH dated on 2019-03-22: Recro Pharma Receives CRL from the FDA for IV Meloxicam

Financial news for REPH dated on 2019-03-22: Recro Pharma Shares Halted News Pending

Financial news for REPH dated on 2019-03-04: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Financial news for REPH dated on 2019-02-25: Recro Pharma Highlights Publication Of Phase III IV Meloxicam Safety, Opioid Use Data In Journal Clinical Pharmacology in Drug Development

Financial news for REPH dated on 2019-02-20: Recro Pharma Announces New IV Meloxicam Data Publication In The Journal Regional Anesthesia & Pain Medicine

Financial news for REPH dated on 2019-02-19: Recro Pharma Files For \$100M Mized Shelf Offering

Financial news for REPH dated on 2019-02-19: Recro Pharma Q4 EPS \$(1.92) Misses \$(0.75) Estimate, Sales \$17.78M Beat \$16.05M Estimate

Financial news for REPH dated on 2019-02-11: Recro Pharma Announces a 5 Year Supply Contract with Novartis Pharma

Financial news for REPH dated on 2019-01-31: Janney Capital Assumes Recro Pharma at Buy

Financial news for REPH dated on 2018-12-21: Recro Pharma Amends IV Meloxicam License Agreement With Alkermes

Financial news for REPH dated on 2018-11-07: Recro Pharma Sees FY2018 Sales \$75.0M vs \$73.46M Est

Financial news for REPH dated on 2018-11-07: Recro Pharma Q3 EPS \$(0.64) Beats \$(0.70) Estimate, Sales \$18.283M Beat \$16.73M Estimate

Financial news for REPH dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for REPH dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for REPH dated on 2018-10-08: Recro Pharma Announces the FDA Set a

PDUFA Date of March 24, 2019 for Recro's New Drug Application for Intravenous Meloxicam

Financial news for REPH dated on 2018-09-06: 54 Biggest Movers From Yesterday

Financial news for REPH dated on 2018-09-05: 55 Biggest Movers From Yesterday

Financial news for REPH dated on 2018-09-04: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for REPH dated on 2018-09-04: Mid-Morning Market Update: Markets Open Lower; Conn's Profit Tops Estimates

Financial news for REPH dated on 2018-09-04: Recro Pharma shares are up 21.2% after the company announced it plans to resubmit a New Drug Application (NDA) for postoperative pain management therapy, IV meloxicam.

Financial news for REPH dated on 2018-09-04: After Type A Meeting With FDA, Recro Pharma Now Anticipates Resubmitting NDA For IV Meloxicam By The End Of September; NDA Will Incorporate Revised Language Relating To Product And Label

Financial news for REPH dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmad's Antibiotic Faces FDA Panel

Financial news for REPH dated on 2018-08-07: Recro Pharma Q2 EPS \$(0.62) Beats \$(1.34) Estimate, Sales \$21.739M Beat \$16.66M Estimate

Financial news for REPH dated on 2018-08-06: Recro Pharma Q2 Earnings Preview

Financial news for REPH dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for REPH dated on 2018-06-26: Recro Pharma Reports Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal

Financial news for REPH dated on 2018-05-25: Benzinga's Weekly Movers For The Week Of May 25, 2018

Financial news for REPH dated on 2018-05-25: Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

Financial news for REPH dated on 2018-05-25: 26 Stocks Moving In Friday's Pre-Market Session

Financial news for REPH dated on 2018-05-25: 45 Biggest Movers From Yesterday

Financial news for REPH dated on 2018-05-24: Mid-Afternoon Market Update: Crude Oil Down Over 1%; Recro Pharma Shares Slide

Financial news for REPH dated on 2018-05-24: 42 Stocks Moving In Thursday's Mid-Day Session

Financial news for REPH dated on 2018-05-24: Mid-Day Market Update: Westell Drops Following Weak Q4 Earnings; Destination Maternity Shares Climb

Financial news for REPH dated on 2018-05-24: Mid-Morning Market Update: Markets Open Lower; McKesson Earnings Miss Estimates

Financial news for REPH dated on 2018-05-24: FDA Declines Recro's IV Meloxicam Application

Financial news for REPH dated on 2018-05-24: Recro Pharma Shares Down 50.1% Premarket After FDA Issued CRL Saying It Could Not Approve IV Meloxicam In Its Current Form

Financial news for REPH dated on 2018-05-24: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for REPH dated on 2018-05-24: Recro Pharma Shares Resume Trade, Down 57.7%

Financial news for REPH dated on 2018-05-24: Recro Pharma Shares To Resume Trade At 7:30 p.m. EDT

Financial news for REPH dated on 2018-05-24: Recro Pharma Receives Complete Response Letter from the FDA, Company to Host Conference Call Today at 8:00 AM ET

Financial news for REPH dated on 2018-05-24: Recros Pharma Shares Halted News Pending

Financial news for REPH dated on 2018-05-23: Benzinga's Daily Biotech Pulse: Inmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Financial news for REPH dated on 2018-05-21: The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Financial news for REPH dated on 2018-05-09: Recro Pharma Q1 EPS \$(0.65) Beats \$(0.70) Estimate, Sales \$19.54M Beat \$17.74M Estimate

Financial news for REPH dated on 2018-05-07: Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam

Financial news for REPH dated on 2018-05-01: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Financial news for REPH dated on 2018-04-05: Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO Business

Financial news for REPH dated on 2018-03-02: 45 Biggest Movers From Yesterday

Financial news for REPH dated on 2018-03-01: 34 Stocks Moving In Thursday's Mid-Day Session

Financial news for REPH dated on 2018-02-14: Oppenheimer Initiates Coverage On Recro Pharma with Outperform Rating, Announces \$19.00 Price Target

Financial news for REPH dated on 2018-01-03: Recro Pharma Announces Michael Celano COO and Ryan Lake CFO

Financial news for REPH dated on 2017-11-09: Recro Pharma Raises FY17 Sales From \$60-\$63M To \$65M

Financial news for REPH dated on 2017-11-09: Recro Pharma Reports Q3 EPS \$(0.48) vs \$(0.75) Est., Sales \$17.11M vs \$13.68M Est.

Financial news for REPH dated on 2017-10-10: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for REPH dated on 2017-10-10: Recro Pharma Offers Phase III IV Meloxicam Efficacy Data In Patients Following Abdominoplasty: 30mg Showed 'Statistically Significant Reductions in Pain, Along with Reductions in Opioid Rescue Use and Improvements in Several Other Pain Relief Metrics'

Financial news for REPH dated on 2017-10-05: Recro Pharma Reports PDUFA Date For IV Meloxicam 30mg As May 26, 2018

Financial news for REPH dated on 2017-09-28: Recro Pharma Reports FDA Acceptance For Review Of NDA For IV Meloxicam 30mg

Financial news for REPH dated on 2017-08-10: Recro Pharma Reports Q2 EPS \$(0.48) vs \$(0.53) Est., Sales \$16.934M vs \$14.6M Est.

Financial news for REPH dated on 2017-07-31: Recro Pharma Submits NDA to the FDA for Meloxicam

Financial news for REPH dated on 2017-07-31: Recro Pharma Submits NDA for IV Meloxicam 30mg

Financial news for REPH dated on 2017-07-05: Recro Pharma Reports Purchase Of Novel Neuromuscular Blocking Agents, Proprietary Chemical Reversal Agent From Cornell, Terms Not Disclosed

Financial news for REPH dated on 2017-07-05: Recro Pharma Acquires Novel Neuromuscular Blocking Agents from Cornell, Terms not Disclosed

Financial news for REPH dated on 2017-05-18: Recro Pharma Offers Poster Presentation Ahead of American Pain Society Meeting, Highlights 'Clinical Performance of IV Meloxicam 30mg, Including Statistically Significant Differences in SPID48 and Numerous Other Rescue Use and Pain Relief Metrics'

Financial news for REPH dated on 2017-05-17: Exclusive: Recro Pharma CEO Talks Meloxicam Non-Opioid Product Ahead Of APS Annual Meeting

Financial news for REPH dated on 2017-05-11: Recro Pharma Reports Q1 EPS \$(0.42) vs \$(0.58) Est., Sales \$18.7M vs \$15.1M Est.

Financial news for REPH dated on 2017-05-09: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for REPH dated on 2017-05-09: UPDATE: Recro Pharma Says Co. On Track to File NDA for IV Meloxicam in Early Q3'17

Financial news for REPH dated on 2017-05-09: Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam

Financial news for REPH dated on 2017-03-06: Recro Pharma Says, with Q4, FY16 Earnings Report, On Track to File NDA with FDA for IV Meloxicam in Summer '17

Financial news for REPH dated on 2017-03-06: Recro Pharma Sees FY17 Sales \$55M-\$60M vs \$60M Est.

Financial news for REPH dated on 2017-03-06: Recro Pharma Reports FY16 EPS \$(2.82) vs \$(2.94) Est., Sales \$69.337M vs \$65.3M Est.

Financial news for REPH dated on 2017-01-18: Exclusive: Recro Pharma CEO Talks Meloxicam, Alleviating Investor Concerns

Financial news for REPH dated on 2016-12-19: 15 Biggest Mid-Day Gainers For Monday

Financial news for REPH dated on 2016-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2016

Financial news for REPH dated on 2016-12-19: PiperJaffray Initiates Coverage On Recro Pharma at Overweight, Announces \$12.00 Target

Financial news for REPH dated on 2016-12-16: Deerfield Mgmt, L.P. Reports 10.9% Passive Stake in Recro Pharma in 13G

Financial news for REPH dated on 2016-12-13: Recro Pharma Prices 6.5M Offering At \$6/Share

Financial news for REPH dated on 2016-12-13: 10 Stocks With Lowest Close In Three Weeks

Financial news for REPH dated on 2016-12-08: Former Insys Execs Charged With Bribery, Racketeering

Financial news for REPH dated on 2016-12-08: Recro Pharma Announces Proposed Public Offering of Common Stock

Financial news for REPH dated on 2016-12-08: Recro Pharma Enters into Amendment to Purchase and Sale Agreement with Alkermes; Recro May Defer Milestone Payment Until Approval of NDA for Intravenous Meloxicam

Financial news for REPH dated on 2016-12-01: Recro Pharma Shares Down 14% On Earlier S-1 Filing Showing \$57.5M Offering

Financial news for REPH dated on 2016-12-01: Recro Pharma CEO Discusses Strong Results In Non-Opioid Pain Treatment Study

Financial news for REPH dated on 2016-11-28: Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro Pharma Shares Surge

Financial news for REPH dated on 2016-11-28: 12 Biggest Mid-Day Gainers For Monday

Financial news for REPH dated on 2016-11-28: Mid-Day Market Update: Crude Oil Up Over 2%; PhaseRx Shares Spike Higher

Financial news for REPH dated on 2016-11-28: Recro's Late-Stage IV Meloxicam Trial Results Rocket Stock Skyward

Financial news for REPH dated on 2016-11-28: Roth Out Positive On Recro Pharma, Increases Probability From ~50% Chance To 75% Of IV meloxicam Approval; Would Add ~\$5-7/Share Increase In PT

Financial news for REPH dated on 2016-11-28: Mid-Morning Market Update: Markets Open Lower; Edwards Lifesciences To Buy Valtech Cardio

Financial news for REPH dated on 2016-11-28: Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam, Achieves Primary Endpoint And 10 Secondary Endpoints; Estimates USNDA Filing Summer 2017

Financial news for REPH dated on 2016-11-10: Recro Pharma Reports Q3 EPS \$(0.50) vs. Est. \$(0.71), Rev. \$19.5M vs. Est. \$13.5M

Financial news for REPH dated on 2016-10-03: Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating

Financial news for REPH dated on 2016-10-03: Benzinga's Top Initiations

Financial news for REPH dated on 2016-10-03: Brean Capital Assumes Recro Pharma at Buy, Announces \$21.00 PT

Financial news for REPH dated on 2016-09-16: Roth Capital Initiates Coverage on Recro Pharma at Buy

Financial news for REPH dated on 2016-09-12: Recro Pharma Releases Slide Presentation

Financial news for REPH dated on 2016-08-29: Benzinga's Top Initiations

Financial news for REPH dated on 2016-08-29: Janney Capital Initiates Coverage on Recro Pharma at Buy

Financial news for REPH dated on 2016-08-16: Recro Pharma Prices Offering of ~1.987M Shares at \$7.50/Share

Financial news for REPH dated on 2016-08-15: Recro Pharma Announces Proposed Public Offering of Common Stock

Financial news for REPH dated on 2016-08-11: Recro Pharma Reports Q2 EPS \$(0.83) vs. Est. (0.78), Rev. \$17.27M vs. Est. \$15.4M

Financial news for REPH dated on 2016-07-27: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for REPH dated on 2016-07-27: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for REPH dated on 2016-07-26: Recro Pharma Shares Up 51% Upon Resumption

Financial news for REPH dated on 2016-07-26: Recro Pharma Shares to Resume Trade 4:35 p.m. EDT

Financial news for REPH dated on 2016-07-26: Recro Pharma Reports Top-Line Results from Phase III Trial of IV Meloxicam: Met Primary Endpoint, Fifteen of Nineteen Secondary Endpoints Achieved

Financial news for REPH dated on 2016-07-26: Recros Pharma Shares Halted News Pending

Financial news for REPH dated on 2016-07-05: Recro Pharma Names Michael Celano CFO

Financial news for REPH dated on 2016-05-12: Recro Pharma Reports Q1 EPS \$(0.71) vs. Est. \$(0.66), Rev. \$17.7M vs. Est. \$13M

Financial news for REPH dated on 2016-03-24: Recro Pharma Reports FY15 EPS \$0.21 vs \$(2.79) in Same Qtr. Last Year, Sales \$51.952M vs \$47.7M Est.

Financial news for REPH dated on 2016-02-16: Recro Pharma Names Fred Graff as Chief Commercial Officer

Financial news for REPH dated on 2016-01-27: Recro Pharma Reports Initiation of Pivotal Phase III Trial of IV Meloxicam for Acute Postoperative Pain

Financial news for REPH dated on 2016-01-06: Recro Pharma Reports Meloxicam Well Tolerated with Statistically Significant Analgesic Effect

Financial news for REPH dated on 2016-01-06: Recro Pharma Says Co. On Track to Initiate Pivotal Phase III in Q1'16

Financial news for REPH dated on 2015-12-02: Recro Pharma Names Dr. Stewart McCallum Chief Medical Officer

Financial news for REPH dated on 2015-11-13: Recro Pharma Reports Q3 EPS (\$0.24) vs. Est. (\$0.20), Rev. \$16.539M vs. Est. \$15.25M

Financial news for REPH dated on 2015-10-26: UPDATE: Recro Pharma Announces IV Meloxicam Advancing to Phase III, Pivotal Trials Expected to Commence in Q1'16

Financial news for REPH dated on 2015-10-26: Recro Pharma Issues Pipeline Update

Financial news for REPH dated on 2015-09-02: Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating

Financial news for REPH dated on 2015-08-20: S-3 from Recro Pharma Shows Registration for \$100M Mixed Securities Shelf Offering

Financial news for REPH dated on 2015-08-14: Recro Pharma Reports Q2 EPS \$(0.17) vs.

Est. \$(0.03), Rev. \$18.66M vs. Est. \$15M

Financial news for REPH dated on 2015-07-24: Recro Pharma Reports Additional Information for Phase II Clinical Trial of Dex-IN

Financial news for REPH dated on 2015-07-17: Market Update: Google & Hertz Among Mid-Day Movers, Germany Votes In Favor Of Greece Bailout And More

Financial news for REPH dated on 2015-07-17: Benzinga's Volume Movers

Financial news for REPH dated on 2015-07-17: Morning Market Gainers

Financial news for REPH dated on 2015-07-17: Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of Dex-IN

Financial news for REPH dated on 2015-07-13: Form D from Recro Pharma Shows Co. Sold ~\$16M in Equity Financing

Financial news for REPH dated on 2015-07-01: Recro Pharma Announces Purchase Agreement To Issues & Sell 1.379M Shares Of Stock At \$11.60/Share For Gross Proceeds Of \$16M

Financial news for REPH dated on 2015-06-09: Recro Pharma CEO Henwood Buys 4,500 Shares @\$8.92/Share -Form 4

Financial news for REPH dated on 2015-04-09: Recro Pharma Provides Update on Continuing Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery

Financial news for REPH dated on 2015-04-09: Recro Pharma Announces Update on On-Going Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery

Financial news for REPH dated on 2015-03-09: Morning Market Gainers

Financial news for REPH dated on 2015-03-09: Recro Pharma to Acquire IV/IM Meloxicam, Gainesville, GA GMP Manufacturing Facility, Business Unit from Alkermes for \$50M

Financial news for REPH dated on 2015-02-03: Recro Pharma In Share Buy Back With Aspire For \$10M Shares, Recro Can Raise \$10M Over 2 Years

Financial news for REPH dated on 2014-12-16: Stocks Hitting 52-Week Lows

Financial news for REPH dated on 2014-12-09: Aegis Capital Downgrades Recro Pharma, Says Investors Should Be Cautious

Financial news for REPH dated on 2014-12-09: Aegis Capital Downgrades Recro Pharma to Hold

Financial news for REPH dated on 2014-11-10: Recro Pharma Reports Q3 EPS of \$(0.61) vs \$(0.51) Est

Financial news for REPH dated on 2014-10-29: Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery

Financial news for REPH dated on 2014-09-05: Stocks Hitting 52-Week Lows

Financial news for REPH dated on 2014-09-05: Morning Market Losers

Financial news for REPH dated on 2014-09-04: PREVIEW: Recro Pharma to Resume Trading at 5:20 PM ET

Financial news for REPH dated on 2014-09-04: Recro Pharma Says Trial Study Not Seen Reaching Statistical Significance

Financial news for REPH dated on 2014-09-04: Recro Pharma Shares Halted, News Pending

Financial news for REPH dated on 2014-08-12: Recro Pharma Reports Q2 EPS of \$(0.36) vs \$(0.25) Est

Financial news for REPH dated on 2014-06-17: UPDATE: Recro Pharma Expecting Top-Line Data by End of 2014

Financial news for REPH dated on 2014-06-17: Recro Pharma Announces Dosing of First Patient in Phase IIb Trial of Dex-IN for Treatment of Acute Pain Following Surgery

Financial news for REPH dated on 2014-06-12: Aegis Capital Initiates Coverage Recro Pharma with Buy Rating, \$40 Price Target

Financial news for REPH dated on 2014-05-12: Recro Pharma Reports Q1 EPS of \$(3.67) Which May Not Compare \$(0.36) Est

Financial news for REPH dated on 2014-03-12: Recro Pharma Closes IPO, Sees Total Gross Proceeds \$34.5M

Financial news for REPH dated on 2014-03-12: Recro Pharma Announces Closing of Initial Public Offering

Financial news for REPH dated on 2014-03-07: Shares of Recro Pharma Open for Trade at \$8.53 After Pricing at \$8/Share

Financial news for REPH dated on 2014-03-07: Waiting on One More IPO This Morning, Recro Pharma: Expected to Open for Trade at 10:50AM EST, Priced 3.75M Shares at \$8/Share